Indian Pharmaceutical Industry Projected to Reach USD 130 Billion by 2030, Driven by Exports, Policy Push

Why It Matters

The rapid scale‑up strengthens India’s role in global drug supply, drives economic growth, and offers investors a high‑potential, policy‑backed market.

Key Takeaways

• Domestic market to hit $130B by 2030.
• Exports reached $30.5B in 2024‑25, 16x 2000 levels.
• EU, UK, NZ FTAs grant zero‑duty market access.
• PLI schemes attracted $40.9B investment, created 97k jobs.
• FDI rose to Rs 13,193 crore in FY26.

Pulse Analysis

India’s pharma surge is more than a statistical uptick; it reflects a strategic shift toward becoming the world’s most reliable source of affordable medicines. While the sector already ranks third by volume, its export basket now spans 191 countries, with half of shipments destined for highly regulated markets such as the United States and Europe. This diversification mitigates tariff risks and reinforces confidence in Indian manufacturing standards, especially as the country hosts the largest number of USFDA‑approved plants outside the United States.

Policy levers are accelerating this momentum. Recent free‑trade agreements with the EU, UK and New Zealand eliminate duties on dozens of pharmaceutical lines, opening a combined $572 billion market to Indian exporters. Simultaneously, the Production‑Linked Incentive framework has mobilised over $40 billion in private capital, spurring the creation of 97,000 jobs and reducing import dependence on critical APIs. Infrastructure parks for bulk drugs and medical devices, backed by central grants, further streamline supply chains and lower production costs, making Indian firms more competitive on price and quality.

For investors and global health stakeholders, the outlook is compelling. The projected $130 billion market size by 2030 signals robust demand growth, while the government’s emphasis on innovation—through schemes like Biopharma SHAKTI—aims to shift the mix toward high‑value biologics and biosimilars. Combined with rising foreign direct investment, these dynamics suggest a resilient, export‑driven growth trajectory that will shape global drug pricing, accessibility, and supply‑chain stability for years to come.